CA2620294A1 - Ocular gene therapy using avalanche-mediated transfection - Google Patents
Ocular gene therapy using avalanche-mediated transfection Download PDFInfo
- Publication number
- CA2620294A1 CA2620294A1 CA002620294A CA2620294A CA2620294A1 CA 2620294 A1 CA2620294 A1 CA 2620294A1 CA 002620294 A CA002620294 A CA 002620294A CA 2620294 A CA2620294 A CA 2620294A CA 2620294 A1 CA2620294 A1 CA 2620294A1
- Authority
- CA
- Canada
- Prior art keywords
- set forth
- cells
- tissue
- nucleic acid
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001890 transfection Methods 0.000 title claims abstract description 31
- 230000001404 mediated effect Effects 0.000 title claims description 14
- 238000001415 gene therapy Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 54
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 37
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 37
- 208000022873 Ocular disease Diseases 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 105
- 210000001519 tissue Anatomy 0.000 claims description 94
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 230000001225 therapeutic effect Effects 0.000 claims description 29
- 239000013612 plasmid Substances 0.000 claims description 28
- 239000003550 marker Substances 0.000 claims description 24
- 102100034343 Integrase Human genes 0.000 claims description 11
- 108010061833 Integrases Proteins 0.000 claims description 11
- 206010025421 Macule Diseases 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 108091006047 fluorescent proteins Proteins 0.000 claims description 7
- 102000034287 fluorescent proteins Human genes 0.000 claims description 7
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 5
- 210000003786 sclera Anatomy 0.000 claims description 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 3
- 210000003161 choroid Anatomy 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 230000000508 neurotrophic effect Effects 0.000 claims description 3
- 210000004127 vitreous body Anatomy 0.000 claims description 3
- 102000016550 Complement Factor H Human genes 0.000 claims description 2
- 108010053085 Complement Factor H Proteins 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 210000001423 scleral cell Anatomy 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000005684 electric field Effects 0.000 abstract description 29
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000008823 permeabilization Effects 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 17
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 16
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 241000701022 Cytomegalovirus Species 0.000 description 12
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 238000005215 recombination Methods 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000013519 translation Methods 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000009834 vaporization Methods 0.000 description 4
- 230000008016 vaporization Effects 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 108091008601 sVEGFR Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- -1 "Sleepifzg Beauty") Proteins 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241001144416 Picornavirales Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000027076 Uveal disease Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000416 anti-micotic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70848605P | 2005-08-15 | 2005-08-15 | |
US60/708,486 | 2005-08-15 | ||
US36098406A | 2006-02-22 | 2006-02-22 | |
US11/360,984 | 2006-02-22 | ||
PCT/US2006/032249 WO2007022403A2 (en) | 2005-08-15 | 2006-08-15 | Ocular gene therapy using avalanche-mediated transfection |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2620294A1 true CA2620294A1 (en) | 2007-02-22 |
Family
ID=37758427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002620294A Abandoned CA2620294A1 (en) | 2005-08-15 | 2006-08-15 | Ocular gene therapy using avalanche-mediated transfection |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1924698A4 (ja) |
JP (1) | JP2009507780A (ja) |
AU (1) | AU2006279395A1 (ja) |
CA (1) | CA2620294A1 (ja) |
WO (1) | WO2007022403A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226790B2 (en) | 2011-02-01 | 2016-01-05 | M.O.E. Medical Devices Llc | Plasma-assisted skin treatment |
US9351790B2 (en) | 2011-09-17 | 2016-05-31 | M.O.E. Medical Devices Llc | Electrode geometries and method for applying electric field treatment to parts of the body |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101169B2 (en) * | 2005-02-23 | 2012-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Ocular gene therapy using avalanche-mediated transfection |
WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
WO2012086702A1 (ja) * | 2010-12-24 | 2012-06-28 | タカラバイオ株式会社 | 遺伝子導入方法 |
EP2670477B1 (en) * | 2011-02-01 | 2015-11-25 | Moe Medical Devices LLC | Plasma-assisted skin treatment |
EP2760536A4 (en) * | 2011-09-17 | 2015-05-06 | Moe Medical Devices Llc | MACHINE-READABLE SYSTEMS, METHODS AND PROGRAMS FOR THE TREATMENT OF ELECTRIC FIELD AND / OR PLASMA-ASSISTED ONYCHOMYCOSES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
-
2006
- 2006-08-15 EP EP06801803A patent/EP1924698A4/en not_active Withdrawn
- 2006-08-15 WO PCT/US2006/032249 patent/WO2007022403A2/en active Application Filing
- 2006-08-15 AU AU2006279395A patent/AU2006279395A1/en not_active Abandoned
- 2006-08-15 JP JP2008527156A patent/JP2009507780A/ja active Pending
- 2006-08-15 CA CA002620294A patent/CA2620294A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226790B2 (en) | 2011-02-01 | 2016-01-05 | M.O.E. Medical Devices Llc | Plasma-assisted skin treatment |
US9351790B2 (en) | 2011-09-17 | 2016-05-31 | M.O.E. Medical Devices Llc | Electrode geometries and method for applying electric field treatment to parts of the body |
Also Published As
Publication number | Publication date |
---|---|
AU2006279395A1 (en) | 2007-02-22 |
WO2007022403A3 (en) | 2010-04-22 |
EP1924698A2 (en) | 2008-05-28 |
JP2009507780A (ja) | 2009-02-26 |
WO2007022403A2 (en) | 2007-02-22 |
EP1924698A4 (en) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8101169B2 (en) | Ocular gene therapy using avalanche-mediated transfection | |
KR102218067B1 (ko) | Aav sflt-1을 사용한 amd의 치료 | |
CA2620294A1 (en) | Ocular gene therapy using avalanche-mediated transfection | |
CN108486152A (zh) | 转基因猪的培育方法和应用 | |
CN110295149B (zh) | 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法 | |
White et al. | GFP‐centrin as a marker for centriole dynamics in living cells | |
KR20180099719A (ko) | 눈 장애에 대한 유전자 요법 | |
CN110891418B (zh) | 对未孵化卵中的禽类胚胎进行性别确定的方法及其用具 | |
CN113512564A (zh) | 以iPSC来源的细胞为载体、基因治疗湿性年龄相关性黄斑变性 | |
KR20190042473A (ko) | 중증 혈소판 감소 증후군 바이러스 예방 및 치료용 유전자 백신 | |
CN110218732B (zh) | 一种非洲猪瘟病毒串联基因、共表达载体、构建方法及应用 | |
CN110607324A (zh) | 奶牛溶菌酶基因乳腺特异性表达重组质粒及其构建方法和应用 | |
CN102061310B (zh) | 人fhl1c真核表达载体的构建及其应用 | |
CN111500635B (zh) | 一种包含携带核酸分子的载体的试剂盒 | |
CN110295180B (zh) | 一种3型鸭甲肝病毒突变基因isa-a117c-c4334a及构建方法 | |
CN110684781B (zh) | 一种3型鸭甲肝病毒突变基因isa-a117c-t1142a及构建方法 | |
CN113943749B (zh) | 一种基于crispr基因编辑系统提高同源重组效率的方法 | |
TW202307213A (zh) | 血管收縮素轉化酶ii(ace2)基因轉殖動物及其用途 | |
CN110484546B (zh) | 一种3型鸭甲肝病毒突变基因isa-c4334a及构建方法 | |
CN110283835B (zh) | 一种3型鸭甲肝病毒突变基因isa-t1142a-c4334a及构建方法 | |
CN110295148A (zh) | 一种快速构建3型鸭甲肝病毒反向遗传株的方法 | |
CN110643634A (zh) | 奶牛气管抗菌肽基因乳腺特异性表达重组质粒及其构建方法和应用 | |
CN102242116B (zh) | 细胞肌动蛋白结合蛋白siRNA干扰片段及其融合表达载体和该表达载体的医药用途 | |
CN110283836B (zh) | 一种3型鸭甲肝病毒突变基因isa-t1142a及构建方法 | |
CN110283834B (zh) | 一种3型鸭甲肝病毒突变基因isa-a117c及构建方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |